Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Utilization of Investigations for Neurotoxicity in CD19 and BCMA CART Recipients

Lauren N Scott, William Wesson, Pilar Thangwaritorn, Raeef L Rahman, Forat Lutfi, Marc Hoffmann, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Al-Ola Abdallah, Sunil Abhyankar, Joseph P. McGuirk, Muhammad Mahdi Nashatizadeh, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 389.

https://doi.org/10.1182/blood-2024-205983

Published: 2024

Journal Articles

Real-World Experience of Infections with T-Cell Engagers in Multiple Myeloma and Non-Hodgkin's Lymphoma

Jordan Snyder, Dennis Grauer, Nausheen Ahmed, Al-Ola Abdallah, Marc Hoffmann, Zahra Mahmoudjafari

Blood (2024) 144 (Supplement 1): 935.

https://doi.org/10.1182/blood-2024-199893

Published: 2024

Journal Articles

The Impact of Financial Support on the Development of Clinical Research in Multiple Myeloma: An in-Depth Analysis (1980-2024)

Anas Zayad, Nausheen Ahmed, Zahra Mahmoudjafari, Barry Skikne, Tara L. Lin, Muhammad Umair Mushtaq, Joseph P. McGuirk, Al-Ola Abdallah, Omar Alkharabsheh, Shebli Atrash

Blood (2024) 144 (Supplement 1): 2288.

https://doi.org/10.1182/blood-2024-205757

Published: 2024

Journal Articles

Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 2411.7.

https://doi.org/10.1182/blood-2024-204158

Published: 2024

Journal Articles

Comparative Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter Study

Razan Mansour, Kimberly M Green, Mark Chang, Gray Magee, James A Davis, Shebli Atrash, Nausheen Ahmed, Muhammad Umair Mushtaq, Evguenia Ouchveridze, Zahra Mahmoudjafari, Al-Ola Abdallah, Barry Paul, Nicole Twardowski, Hamza Hashmi

Blood (2024) 144 (Supplement 1): 1965.

https://doi.org/10.1182/blood-2024-209196

Published: 2024

Journal Articles

Exploring the Global Landscape of Open Access Publication Models and Their Correlation with the Impact Factor in the Field of Hematology/Oncology

Emily J Casteen, Lauren N Scott, Raeef L Rahman, Zahra Mahmoudjafari, Faiz Anwer, Muhammad Umair Mushtaq, Evguenia Ouchveridze, Al-Ola Abdallah, Shebli Atrash, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 7950.

https://doi.org/10.1182/blood-2024-204130

Published: 2024

Journal Articles

A Real-World Analysis of the Safety and Efficacy of BCMA-Directed CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Alma Habib, Nausheen Ahmed, Abdullah Mohammad Khan, Darryl Chang, Barry Paul, Hira Shaikh, Christopher Strouse, Emily Struble, Andrew Vegel, James A Davis, Kimberly M Green, Hamza Hashmi, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Joseph P. McGuirk, Al-Ola Abdallah, Shebli Atrash, Reed Friend

Blood (2024) 144 (Supplement 1): 2009.

https://doi.org/10.1182/blood-2024-208799

Published: 2024

Journal Articles

The Scope of Academic and Industry Sponsorship in Shaping the Future of AL Amyloidosis Research

Anas Zayad, Nausheen Ahmed, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Evguenia Ouchveridze, Forat Lutfi, Joseph P. McGuirk, Al-Ola Abdallah, Faiz Anwer, Manisha Bhutani, Shebli Atrash

Blood (2024) 144 (Supplement 1): 7595.

https://doi.org/10.1182/blood-2024-205422

Published: 2024

Journal Articles

Real-World Incidence of Infections in BCMA-Targeting Bi-Specific Antibodies in Relapsed/Refractory Multiple Myeloma

Jordan Snyder, Jessica McElwee, Hailey Hill, Donald C Moore, Shebli Atrash, Myra Robinson, Ferdous Ahmed, Al-Ola Abdallah, Zahra Mahmoudjafari, Nausheen Ahmed, Grace Elsey

Blood (2024) 144 (Supplement 1): 7845.

https://doi.org/10.1182/blood-2024-208961

Published: 2024

Journal Articles

Outcomes of Double-Hit and Single High Risk Cytogenetic Newly Diagnosed Myeloma in Transplant Eligible Patients

Raeef L Rahman, Aroog Khaliq, Mehak M Laharwal, Shebli Atrash, Joseph P. McGuirk, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Al-Ola Abdallah, Nausheen Ahmed, Prerna Mewawalla, Jordan Snyder

Blood (2024) 144 (Supplement 1): 6953.

https://doi.org/10.1182/blood-2024-206098

Published: 2024

Journal Articles

Characterizing Treatment Patterns in Multiple Myeloma Patients with High-Risk Cytogenetics: A 15-Year-Study

Priyanka Venkatesh, Raeef L Rahman, Aroog Khaliq, Mehak M Laharwal, Shebli Atrash, Joseph P. McGuirk, Forat Lutfi, Muhammad Umair Mushtaq, Al-Ola Abdallah, Nausheen Ahmed, Prerna Mewawalla, Jordan Snyder, Zahra Mahmoudjafari

Blood (2024) 144 (Supplement 1): 6943.

https://doi.org/10.1182/blood-2024-211572

Published: 2024

Journal Articles

Stalled CARS. Examining the Real-World Impact of Waiting for CART in Patients with Multiple Myeloma

Michael Weise, Muhammad Umair Mushtaq, Shebli Atrash, Al-Ola Abdallah, Joseph P. McGuirk, Forat Lutfi, Barry Skikne, Nausheen Ahmed, Zahra Mahmoudjafari

Blood (2024) 144 (Supplement 1): 6937.

https://doi.org/10.1182/blood-2024-208299

Published: 2024

Journal Articles

Efficacy of BCMA T-Cell Engagers (TCE) Vs. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Following BCMA-Directed Therapies, Relapsed/Refractory Multiple Myeloma: The Chicken or the Egg Dilemma

Blood (2024) 144 (Supplement 1): 7098.

https://doi.org/10.1182/blood-2024-207398

Published: 2024

Journal Articles

Comparison of Standard of Care with or without a PD-1/Pdl-1 Inhibitor for the Treatment of Multiple Myeloma: A Meta-Analysis of Phase II and III Randomized Controlled Trials

Zain Alsaddi, Ghena Khasawneh, Yara Shatnawi, Nausheen Ahmed, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Al-Ola Abdallah, Barry Paul, Shebli Atrash

Blood (2024) 144 (Supplement 1): 7009.

https://doi.org/10.1182/blood-2024-194933

Published: 2024

Journal Articles

A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Alma Habib, Abdullah Mohammad Khan, Mehak M Laharwal, Prerna Mewawalla, Marshall McKenna, Yun Kyoung Tiger, Hira Shaikh, Christopher Strouse, Kimberly M Green, James A Davis, Hamza Hashmi, Jordan Snyder, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Nausheen Ahmed, Al-Ola Abdallah, Shebli Atrash, Barry Paul, Reed Friend

Blood (2024) 144 (Supplement 1): 7037.

https://doi.org/10.1182/blood-2024-209283

Published: 2024

Journal Articles

Outcomes of Patients with Newly Diagnosed Myeloma Both Transplant Eligible and Ineligible in North Africa: A Usmirc- Morocco/Tunisia Collaboration

Nesrine Ben Sayed, Yosra Ben Youssef, Abederrahim Khélif, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Joseph P. McGuirk, Nausheen Ahmed, Al-Ola Abdallah, Shebli Atrash, Houda Masrar, Kamal Doghmi, El Mehdi Mahtat

Blood (2024) 144 (Supplement 1): 7023.

https://doi.org/10.1182/blood-2024-206259

Published: 2024

Journal Articles

Social Determinants of Health (SDOH) and Access to CART for Multiple Myeloma

Michael Weise, Shebli Atrash, Briha Ansari, Muhammad Umair Mushtaq, Joseph P. McGuirk, Al-Ola Abdallah, Zahra Mahmoudjafari, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 5162.

https://doi.org/10.1182/blood-2024-207882

Published: 2024

Journal Articles

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial

Ishita Kamboj, Darryl Chang, Alma Habib, Andrew Vegel, Emily Struble, Hira Shaikh, Christopher Strouse, James A Davis, Aliya Rashid, Kevin Graf, Kimberly M Green, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Hamza Hashmi, Joseph P. McGuirk, Al-Ola Abdallah, Shebli Atrash, Abdullah Mohammad Khan, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 2411.2.

https://doi.org/10.1182/blood-2024-199187

Published: 2024

Journal Articles

Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study

Darryl Chang, Alma Habib, Andrew Vegel, Emily Struble, Hira Shaikh, Christopher Strouse, Kimberly M Green, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Hamza Hashmi, Joseph P. McGuirk, Abdullah Mohammad Khan, Al-Ola Abdallah, Nausheen Ahmed, Shebli Atrash, Manisha Bhutani

Blood (2024) 144 (Supplement 1): 2404.

https://doi.org/10.1182/blood-2024-208692

Published: 2024

Journal Articles

Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

James A Davis, Jordan Snyder, Mikhaila Rice, Donald C Moore, Christopher Cahoon, Kelley Julian, Charlotte B Wagner, Katelynn Granger, Kimberly M Green, Shebli Atrash, Hailey Hill, Jessica McElwee, Grace Elsey, Jack Khouri, Joslyn Rudoni, Zahra Mahmoudjafari, Victoria Nachar

Blood (2024) 144 (Supplement 1): 2382.

https://doi.org/10.1182/blood-2024-193025

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Utilization of Investigations for Neurotoxicity in CD19 and BCMA CART Recipients

Real-World Experience of Infections with T-Cell Engagers in Multiple Myeloma and Non-Hodgkin's Lymphoma

The Impact of Financial Support on the Development of Clinical Research in Multiple Myeloma: An in-Depth Analysis (1980-2024)

Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma

Comparative Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter Study

Exploring the Global Landscape of Open Access Publication Models and Their Correlation with the Impact Factor in the Field of Hematology/Oncology

A Real-World Analysis of the Safety and Efficacy of BCMA-Directed CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

The Scope of Academic and Industry Sponsorship in Shaping the Future of AL Amyloidosis Research

Real-World Incidence of Infections in BCMA-Targeting Bi-Specific Antibodies in Relapsed/Refractory Multiple Myeloma

Outcomes of Double-Hit and Single High Risk Cytogenetic Newly Diagnosed Myeloma in Transplant Eligible Patients

Characterizing Treatment Patterns in Multiple Myeloma Patients with High-Risk Cytogenetics: A 15-Year-Study

Stalled CARS. Examining the Real-World Impact of Waiting for CART in Patients with Multiple Myeloma

Efficacy of BCMA T-Cell Engagers (TCE) Vs. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Following BCMA-Directed Therapies, Relapsed/Refractory Multiple Myeloma: The Chicken or the Egg Dilemma

Comparison of Standard of Care with or without a PD-1/Pdl-1 Inhibitor for the Treatment of Multiple Myeloma: A Meta-Analysis of Phase II and III Randomized Controlled Trials

A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Outcomes of Patients with Newly Diagnosed Myeloma Both Transplant Eligible and Ineligible in North Africa: A Usmirc- Morocco/Tunisia Collaboration

Social Determinants of Health (SDOH) and Access to CART for Multiple Myeloma

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial

Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study

Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only